Preparation, characterization and anti-colitis activity of curcumin-asafoetida complex encapsulated in turmeric nanofiber

- Ulcerative colitis (UC) is a main form of inflammatory bowel disease (IBD).
- Gut health product (GHP) was formulated by encapsulation of ASF and CUR onto TNF.
- GHP was characterized by UPLC, GC-MS, FTIR, XRD, SEM with EDS and DSC studies.
- GHP was evaluated for anti-colitis activity in a rat model of 5% DSS induced UC.
- GHP has significant protective effects against DSS induced colitis.

Ulcerative colitis (UC) is a main form of inflammatory bowel disease (IBD). Asafoetida (ASF) and turmeric have traditionally been used for the treatment of various inflammatory diseases, including UC, because ASF is rich in sulfur compounds and turmeric contains curcumin (CUR). Turmeric nanofiber (TNF), the modified cell wall component of turmeric is considered to play important role in the human diet, health and can be used as a carrier agent to encapsulate bioactive components. A novel gut health product (GHP) was formulated by encapsulation of ASF and CUR complex onto TNF. The GHP was characterized by UPLC, GC-MS, FTIR, XRD, SEM with EDS and DSC studies. GHP was evaluated for anti-colitis activity in a rat model of 5% dextran sulfate sodium (DSS) induced UC. Treatment with GHP significantly attenuated the disease activity index, colitis score, histopathological changes and myeloperoxidase activity. GHP has significant protective effects against DSS induced colitis.

194